Premium
Use of the FAB Crriteria for the Diagnosis of Acute Erythroleukaemia (AEL)
Author(s) -
Woodruff R. K.,
Buncei I. H.,
Jphnsons S.,
Paxton A. M.,
Malpas J. S.
Publication year - 1981
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1981.tb03728.x
Subject(s) - medicine , chemotherapy , acute myeloblastic leukemia , refractory (planetary science) , complete remission , pediatrics , leukemia , immunology , biology , astrobiology
Use of the FA6 criteria for the diagnosis of acute erythroleukaemia (AEL). R. K. Woodruff, I. H. Bunce, S. Johnson, A. in. Paxton and J. S. malpas, Aust. N.Z. J. med ., 1981, 11, pp. 1–7. The criteria proposed by the French‐American‐British (FAB) Group for the diagnosis of acute erythroleukaemia (AEL), including the requirement for ≥ 30% marrow myeloblasts, were used in a review of patients with erythroleukaemia. Ten patients with AEL were identified, and a further twelve patients with marrows suggestive of AEL but having <30% myeloblasts were classified as having refractory anemia with excess of blasts (RAEB). The AEL patients had a poor prognosis, poor response to chemotherapy, and none showed evolution to myeloblastic or monoblastic leukaemia. In contrast, the patients with RAEB appeared to survive longer, respond better to chemotherapy, and several evolved into typical myelogenous leukaemia The FAB criteria subdivides patients with erythroleukaemia into groups with apparent clinic pathological and prognostic differences. Further studies using these or equally strict criteria are required